Is there a role for ovarian function suppression in operable breast cancer?

被引：0
|
作者：
Joseph A. Sparano
机构：
[1] Albert Einstein College of Medicine,
[2] Montefiore Medical Center,undefined
来源：
Breast Cancer Research and Treatment | 2010年 / 123卷
关键词：
Breast Cancer; Tamoxifen; Premenopausal Woman; Exemestane; Operable Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：311 / 313
页数：2
相关论文
共 50 条
  • [31] Breast cancer treatment and ovarian function
    Yildiz, Sule
    Bildik, Gamze
    Benlioglu, Can
    Turan, Volkan
    Dilege, Ece
    Ozel, Melis
    Kim, Samuel
    Oktem, Ozgur
    REPRODUCTIVE BIOMEDICINE ONLINE, 2023, 46 (02) : 313 - 331
  • [32] THE ROLE OF POSTOPERATIVE RADIOTHERAPY IN THE TREATMENT OF OPERABLE BREAST-CANCER
    BEADLE, GF
    HARRIS, JR
    BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (03) : 159 - 168
  • [33] Triptorelin ovarian suppression during breast cancer chemotherapy
    Elizabeth S. Ginsburg
    Ann H. Partridge
    Nature Reviews Endocrinology, 2011, 7 : 637 - 638
  • [34] DRUG-INDUCED SUPPRESSION OF OVARIAN AND ADRENAL-FUNCTION IN BREAST-CANCER PATIENTS
    DNISTRIAN, AM
    SCHWARTZ, MK
    FRACCHIA, AA
    HAKES, TB
    KAUFMAN, RJ
    CURRIE, VE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 179 - 179
  • [35] Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women
    Scharl, A.
    Salterberg, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2016, 76 (05) : 516 - 524
  • [36] Adjuvant Ovarian Suppression in Premenopausal Breast Cancer REPLY
    Francis, Prudence A.
    Regan, Meredith M.
    Fleming, Gini F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (17): : 1673 - 1673
  • [37] Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
    Pagani, Olivia
    Regan, Meredith M.
    Walley, Barbara A.
    Fleming, Gini F.
    Colleoni, Marco
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo
    Burstein, Harold J.
    Perez, Edith A.
    Ciruelos, Eva
    Stearns, Vered
    Bonnefoi, Herve R.
    Martino, Silvana
    Geyer, Charles E., Jr.
    Pinotti, Graziella
    Puglisi, Fabio
    Crivellari, Diana
    Ruhstaller, Thomas
    Winer, Eric P.
    Rabaglio-Poretti, Manuela
    Maibach, Rudolf
    Ruepp, Barbara
    Giobbie-Hurder, Anita
    Price, Karen N.
    Bernhard, Juerg
    Luo, Weixiu
    Ribi, Karin
    Viale, Giuseppe
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    Francis, Prudence A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 107 - 118
  • [38] Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis
    Azim, Hamdy A.
    Shohdy, Kyrillus S.
    Kaldas, David F.
    Kassem, Loay
    Azim, Hatem A., Jr.
    CURRENT PROBLEMS IN CANCER, 2020, 44 (06)
  • [39] Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients
    Zhang, Jenny J.
    Wang, Molin
    STATISTICS IN MEDICINE, 2010, 29 (22) : 2310 - 2324
  • [40] Use and effectiveness of adjuvant ovarian function suppression (OFS) in premenopausal women with early breast cancer
    Ferreira, A. R.
    Ribeiro, J.
    Mayer, A.
    Brito, M.
    Miranda, A.
    Fernandes, J. P.
    Passos-Coelho, J. L.
    Costa, L.
    Vaz-Luis, I.
    ANNALS OF ONCOLOGY, 2017, 28
12345